Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Fluzone Quadrivalent

- PMLiVE

FDA to review Sanofi’s Lantus successor

Decision on company’s next generation insulin Toujeo expected early next year

- PMLiVE

ADA: Novo says switching to Tresiba could reduce NHS costs

Real world data backs insulin’s ability to reduce hypoglycaemia in people with diabetes

- PMLiVE

ADA: Sanofi shifts focus to embrace integration in diabetes

Pascale Witz unveils company's ambitions at ADA conference

- PMLiVE

Sanofi and Medtronic to develop drug-device combos in diabetes

Companies tell PMLiVE their new alliance will take an ‘open innovation’ approach

- PMLiVE

Sanofi US takes to Pinterest for more visual sharing

Adds the online pin board to its social media toolkit

- PMLiVE

Bayer’s CEO Dekkers to step down

And Sanofi CEO to move to US

- PMLiVE

Sanofi plans OTC version of Lilly’s Cialis

Deal could see erectile dysfunction drug become available without a prescription once its patents expire

National Institute for Health and Care Excellence NICE logo

NICE backs reimbursement of Sanofi’s MS drug Lemtrada

Final guidance opens doors for use on NHS in England and Wales

National Institute for Health and Care Excellence NICE logo

NICE backtracks on prostate cancer drug enzalutamide

Says Astellas and Medivation's Xtandi can be used within the NHS in England and Wales

- PMLiVE

Xtandi on course for pre-chemo use in prostate cancer

US FDA grants priority review to Medivation and Astellas drug

Sanofi reception

Sanofi won’t take part in mega-deal trend

CEO says French firm will stick to bolt-on acquisitions

Sanofi reception

Sanofi launches bursary scheme in UK

Funding to support initiatives that promote patient empowerment and education

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links